AbbVie (NYSE: ABBV), Chicago, IL-based acquired Aliada Therapeutics, a Boston, MA-based biotechnology firm targeted on central nervous system (CNS) illnesses.
The quantity of the deal was not disclosed.
AbbVie will purchase all excellent Aliada fairness for $1.4 Billion in money, topic to sure customary changes. This transaction is anticipated to shut in 4Q2024.
Aliada Therapeutics is a biotechnology firm targeted on addressing supply challenges in CNS drug growth. It’s growing next-generation CNS therapeutics with its novel BBB-crossing Modular Supply (MODEL™) platform know-how, which has been proven to effectively transport numerous therapeutic cargoes into the mind, enhancing effectiveness and addressing the important want for environment friendly and versatile giant molecule and oligonucleotide supply. Its lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a possible best-in-class remedy for Alzheimer’s illness.
Johnson & Johnson (by its enterprise capital arm, Johnson & Johnson Innovation – JJDC, Inc.), RA Capital Administration, and Raven (RA Capital Administration’s incubator) co-founded Aliada and co-led the sequence seed financing in 2021 to advance the MODEL™ platform created by Johnson & Johnson scientists that was licensed to Aliada at its inception. Additional funding was made by OrbiMed and Sanofi Ventures.
FinSMEs
28/10/2024
